Invex Therapeutics Ltd.ASX: IXC

Improved Neuronal Cell Survival in 3D Model of Alzheimer's

· Issued by Invex Therapeutics Ltd.

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Invex Therapeutics Ltd. has released findings on the effects of Exenatide in a three-dimensional model of Alzheimer's Disease, indicating improved neuronal cell survival. The study showed that low and moderate doses of Exenatide significantly increased cell viability under conditions mimicking oxidative stress and ferroptosis, common pathways in Alzheimer's progression.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Invex Therapeutics Ltd. on 6ix

Earlier from Invex Therapeutics

Later from Invex Therapeutics

All Invex Therapeutics news releases